• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Mixed; D.R. Horton Earnings Top Views

    11/7/23 9:46:21 AM ET
    $ALTO
    $DHI
    $PXMD
    $SNTI
    Major Chemicals
    Industrials
    Homebuilding
    Consumer Discretionary
    Get the next $ALTO alert in real time by email

    U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday

    Following the market opening Tuesday, the Dow traded down 0.18% to 34,035.79 while the NASDAQ rose 0.14% to 13,537.65. The S&P 500 also fell, dropping, 0.22% to 4,356.26.

    Check This Out: Top 4 Industrial Stocks That Could Sink Your Portfolio In November

     

    Leading and Lagging Sectors

     

    Information technology shares rose by 0.2% on Tuesday.

    In trading on Tuesday, energy shares fell by 2.1%.


    Top Headline


    D.R. Horton, Inc. (NYSE:DHI) reported better-than-expected earnings for its fourth quarter on Tuesday.

    D.R. Horton posted quarterly earnings of $4.45 per share, topping market estimates of $3.93 per share. The company’s quarterly sales came in at $10.50 billion versus expectations of $10.01 billion.

    D.R. Horton said it sees FY24 consolidated revenues of approximately $36 billion to $37 billion, versus estimates of $36.20 billion.

     

    Equities Trading UP

    PaxMedica, Inc. (NASDAQ:PXMD) shares shot up 117% to $6.62. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

    Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) got a boost, shooting 86% to $0.5442 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti is eligible to receive up to $156 million in milestones and royalties.

    Tharimmune, Inc. (NASDAQ:THAR) shares were also up, gaining 50% to $0.2360 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.


    Equities Trading DOWN

    Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares dropped 82% to $2.5201 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.

    Shares of Alto Ingredients, Inc. (NASDAQ:ALTO) were down 56% to $2.18 after the company reported mixed third-quarter financial results.

    Worldwide Webb Acquisition Corp. (NASDAQ:WWAC) was down, falling 40% to $4.43.

    Also Check This Out: Jim Cramer Says This Tech Company Reported A 'Dynamite' Quarter: 'I Disliked These Guys For A Long Time, Not Anymore'


    Commodities

    In commodity news, oil traded down 1.8% to $79.36 while gold traded down 0.9% at $1,971.70.

    Silver traded down 2.5% to $22.645 on Tuesday while copper fell 1.4% to $3.6665.


    Euro zone


    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.2%, London’s FTSE 100 rose 0.1% while Spain’s IBEX 35 Index fell 0.2% The German DAX fell 0.3% French CAC 40 fell 0.5%, while Italy’s FTSE MIB Index fell 0.1%.

    Industrial producer prices in the Eurozone declined by 12.4% year-over-year in September versus an 11.5% decline a month ago, while the HCOB construction PMI declined to 42.7 in October from 43.6 in September.

    The S&P Global France construction PMI declined to 41 in October from 43.7 in September, while German construction PMI fell to 38.3 in October, recording the lowest reading since April 2020. Industrial production in Germany fell 1.4% month-over-month for September, while UK’s Halifax House Price Index fell by 3.2% year-over-year in October.

     

    Asia Pacific Markets


    Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 1.34%, Hong Kong’s Hang Seng Index declining 1.65% and China’s Shanghai Composite Index falling 0.04%. India’s S&P BSE Sensex, meanwhile, fell around 0.03%.

    China's trade surplus in October 2023 narrowed to $56.53 billion from $82.35 billion in the year-ago-month. Chinese foreign exchange reserves fell to $3.101 trillion in October from the previous month's reading of $3.115 trillion, while foreign exchange reserves in Hong Kong increased to $416 billion in October.


    Economics


    The Logistics Manager’s Index in the U.S. rose to 56.5 in October versus 52.4 in the prior month.

    The Manheim Used Vehicle Value Index fell 2.3% month-over-month for October.

    The trade deficit in the U.S. increased to $61.5 billion in September versus a revised $58.7 billion gap in the prior month and compared to market estimates of $59.9 billion.

    Now Read This: Insiders Selling Amazon, Costco And 2 Other Stocks

    Get the next $ALTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALTO
    $DHI
    $PXMD
    $SNTI

    CompanyDatePrice TargetRatingAnalyst
    D.R. Horton Inc.
    $DHI
    1/7/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    D.R. Horton Inc.
    $DHI
    1/6/2026$155.00Overweight → Equal Weight
    Wells Fargo
    D.R. Horton Inc.
    $DHI
    12/2/2025$186.00Buy
    BTIG Research
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    D.R. Horton Inc.
    $DHI
    10/7/2025$169.00Outperform → In-line
    Evercore ISI
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    D.R. Horton Inc.
    $DHI
    3/6/2025$164.00Neutral → Buy
    Seaport Research Partners
    More analyst ratings

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Sneed James R bought $3,364 worth of shares (3,176 units at $1.06), increasing direct ownership by 0.74% to 432,397 units (SEC Form 4)

    4 - Alto Ingredients, Inc. (0000778164) (Issuer)

    8/14/25 9:34:09 PM ET
    $ALTO
    Major Chemicals
    Industrials

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D.R. Horton downgraded by Citizens JMP

    Citizens JMP downgraded D.R. Horton from Mkt Outperform to Mkt Perform

    1/7/26 8:55:45 AM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    D.R. Horton downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded D.R. Horton from Overweight to Equal Weight and set a new price target of $155.00

    1/6/26 8:45:39 AM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    BTIG Research initiated coverage on D.R. Horton with a new price target

    BTIG Research initiated coverage of D.R. Horton with a rating of Buy and set a new price target of $186.00

    12/2/25 8:25:15 AM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Radkowski Angela Dominy

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:20:49 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sommers Jill E.

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:18:29 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Wiley William Thomas Jr.

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:16:13 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $DHI
    $PXMD
    $SNTI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tharimmune Inc.

    SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)

    2/6/26 4:01:20 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    2/6/26 8:20:38 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) --  Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generatio

    2/11/26 8:35:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel. Senti's presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Reg

    2/3/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) --  Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generatio

    2/11/26 8:35:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel. Senti's presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Reg

    2/3/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    D.R. Horton, Inc., America's Builder, Reports Fiscal 2026 First Quarter Earnings and Declares Quarterly Dividend of $0.45 Per Share

    D.R. Horton, Inc. (NYSE:DHI), America's Builder, today reported its first fiscal quarter results. All comparisons in this release are to the respective prior year period, unless noted otherwise. Fiscal 2026 First Quarter Highlights As of or for the quarter ended December 31, 2025 Net income attributable to D.R. Horton of $594.8 million or $2.03 per diluted share Consolidated pre-tax income of $798.1 million, with a pre-tax profit margin of 11.6% Consolidated revenues of $6.9 billion Home sales revenues of $6.5 billion on 17,818 homes closed Net sales orders increased 3% to 18,300 homes with an order value of $6.7 billion Cash provided by operations totaled $854.0 million

    1/20/26 6:30:00 AM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

    Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

    12/12/25 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALTO
    $DHI
    $PXMD
    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care